Wei Jia, Cao Xiaodan, Zhou Shengmin, Chen Chao, Yu Haijun, Zhou Yao, Wang Ping
State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology, Shanghai 200237, P.R. China.
J Microbiol Biotechnol. 2015 Aug;25(8):1227-33. doi: 10.4014/jmb.1503.03073.
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis through binding to its specific receptors, which mainly occurs to VEGF receptor 2 (VEGFR-2), a kinase insert domain-containing receptor. Therefore, the disruption of VEGFR-2 signaling provides a promising therapeutic approach for the treatment of cancer by inhibiting abnormal or tumorinduced angiogenesis. To explore this potential, we expressed the catalytic domain of VEGFR- 2 (VEGFR-2-CD) as a soluble active kinase in Escherichia coli. The recombinant protein was purified and the VEGFR-2-CD activity was investigated. The obtained VEGFR-2-CD showed autophosphorylation activity and phosphate transfer activity comparable to the commercial enzyme. Furthermore, the IC50 value of known VEGFR-2 inhibitor was determined using the purified VEGFR-2-CD. These results indicated a possibility for functional and economical VEGFR-2-CD expression in E. coli to use for inhibitor screening.
血管内皮生长因子(VEGF)通过与其特异性受体结合在血管生成中起关键作用,这种结合主要发生在VEGF受体2(VEGFR - 2)上,VEGFR - 2是一种含激酶插入结构域的受体。因此,破坏VEGFR - 2信号传导通过抑制异常或肿瘤诱导的血管生成,为癌症治疗提供了一种有前景的治疗方法。为了探索这种潜力,我们在大肠杆菌中表达了VEGFR - 2的催化结构域(VEGFR - 2 - CD)作为可溶性活性激酶。对重组蛋白进行了纯化,并研究了VEGFR - 2 - CD的活性。所获得的VEGFR - 2 - CD表现出与商业酶相当的自磷酸化活性和磷酸转移活性。此外,使用纯化的VEGFR - 2 - CD测定了已知VEGFR - 2抑制剂的IC50值。这些结果表明在大肠杆菌中功能性且经济地表达VEGFR - 2 - CD用于抑制剂筛选是有可能的。